DNA Sequencing Market Size, Share, Forecast, & Trends Analysis by Offering (Kits & Reagents [DNA Extraction, Library Preparation, QC], Instruments, Software), Technology (NGS, Sanger), Application (Clinical, Research) End User - Global Forecast to 2031

DNA Sequencing Market Size, Share, Forecast, & Trends Analysis by Offering (Kits & Reagents [DNA Extraction, Library Preparation, QC], Instruments, Software), Technology (NGS, Sanger), Application (Clinical, Research) End User - Global Forecast to 2031

The global DNA sequencing market is projected to reach $21.30 billion by 2031 at a CAGR of 11.8% from 2024 to 2031.

Succeeding extensive secondary and primary research and in-depth analysis of the market scenario, the report comprises the analysis of key industry drivers, restraints, challenges, and opportunities.

The DNA sequencing market’s growth is driven by several factors, including the decreasing costs of sequencing, the rising incidence of cancer and genetic disorders, the rising use of DNA sequencing in diagnostics and personalized medicine, increased pharmaceutical R&D investments, favorable regulatory and reimbursement policies, high healthcare expenditures, advances in sequencing technology, and supportive government initiatives aimed at promoting the use of sequencing technology in clinical & research applications. However, factors such as the high cost of sequencing consumables, limited identification of actionable mutations for precision medicine, and ethical and legal concerns related to DNA sequencing-based diagnostics restrain this growth.

Moreover, the expanding applications of DNA sequencing, government support for extensive genomic projects, growing awareness and adoption of targeted therapies, and economic growth in emerging markets are anticipated to offer growth opportunities for companies operating in this market. However, regulatory uncertainties, limited expertise & sequencing capabilities among smaller laboratories, a shortage of sequencing professionals in developing regions, and the substantial capital required for NGS infrastructure are some of the challenges impeding the market’s growth.

Key trends in this market include the focus of emerging DNA sequencing companies on technological advancements and cost reduction and the emphasis by major players on developing portable and real-time sequencing technologies.

The report offers a competitive landscape based on an extensive assessment of the key players’ product portfolios and geographical presence and the key growth strategies adopted by them over the past few years (2021–2024). The key players operating in the global DNA sequencing market are Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Revvity, Inc. (U.S.), QIAGEN N.V. (Netherlands), Agilent Technologies, Inc. (U.S.), Pacific Biosciences of California, Inc. (U.S.), Danaher Corporation (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Oxford Nanopore Technologies Plc. (U.K.), and MGI Tech Co., Ltd. (China).

Among the offerings studied in this report, in 2024, the consumables segment is projected to dominate the DNA sequencing market, capturing 73.4% of the total share. The significant market share is attributed to the growing demand for consumables from end users, frequent use of sample preparation materials, increasing affordability, and the expansion of genome mapping programs.

Among the applications studied in this report, in 2024, the research & other applications segment is projected to dominate the DNA sequencing market, capturing 67.2% of the total share. The significant market share is attributed to several factors: the declining cost of sequencing procedures, increased R&D investments by pharmaceutical and biotechnology companies in drug discovery, the expanding use of NGS in various clinical and research settings, and the application of informatics solutions to identify pharmacological targets, validate therapeutic hypotheses, and assess the potential safety of inhibitory compounds targeting molecular sites.

Among the end users studied in this report, in 2024, the pharmaceutical & biotechnology companies segment is projected to dominate the DNA sequencing market, capturing 44.7% of the total share. The significant market share is attributed to increased R&D expenditures by pharmaceutical & biotechnology companies and the growing prevalence of chronic diseases, which are fueling the adoption of next-generation sequencing products.

An in-depth analysis of the geographical scenario of the global DNA sequencing market provides detailed qualitative and quantitative insights into five major regions (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) along with the coverage of major countries in each region. In 2024, North America is projected to dominate the market, capturing 49.0% of the total share. Additionally, in 2024, the U.S. is expected to dominate the DNA sequencing market in North America. The region’s significant market share can be attributed to several factors, including supportive government initiatives for genomic research, expanding applications of sequencing-based studies, the presence of leading next-generation sequencing technology providers, rising research investments by pharmaceutical and biopharmaceutical companies, decreasing sequencing costs, wide availability of advanced sequencing products and solutions, increasing cancer prevalence, and a favorable reimbursement environment in the region.

Scope of the Report:

DNA Sequencing Market Assessment—by Offering

Consumables
Sample Preparation Kits & Reagents
DNA Extraction & Amplification
Quality Control
Other Kits & Reagents
Other Consumables
Instruments
Software
Services

Note: Other Kits & Reagents Include dilution buffers, DNA standards, reagents for DNA cleanup, target enrichment, and other reagents

DNA Sequencing Market Assessment —by Technology

Next-Generation Sequencing
Sequencing by Synthesis
Ion Semiconductor Sequencing
DNA Nanoball Sequencing
Single-molecule Real-time Sequencing
Other NGS Technologies
Sanger Sequencing & Pyrosequencing

Note: Other NGS Technologies Nanopore Sequencing and AVITI Sequencing

DNA Sequencing Market Assessment —by Application

Research & Other Applications
Drug Discovery
Agriculture & Animal Research
Other Applications
Clinical Applications
Reproductive Health
Oncology
Infectious Diseases
Other Clinical Applications

Note: Other Applications include food microbiology, microbiota analysis in the beverage industry, and environmental studies.

Note: Other Clinical Applications include the detection of genetic aberrations in neurological disorders, rare diseases, and metabolic and immune disorders.

DNA Sequencing Market Assessment—by End User

Pharmaceutical & Biotechnology Companies
Hospitals & Diagnostic Laboratories
Academic Institutes & Research Centers
Other End Users

Note: Other End Users include forensic laboratories & security agencies, food & beverage companies, and agriculture companies.

DNA Sequencing Market Assessment—by Geography

North America
U.S.
Canada
Europe
Germany
France
Italy
U.K.
Spain
Rest of Europe (RoE)
Asia-Pacific
China
Japan
India
Rest of Asia-Pacific (RoAPAC)
Latin America
Brazil
Mexico
Rest of Latin America (RoLATAM)
Middle East & Africa

DNA Sequencing Market

Report Metrics	Details
Years Considered	2022 - 2031
Base Year	2023
Forecast Period	2024-2031
Page Count	325
Units Referenced	Value (USD Million)
Segments/Key Topics	Market by Offering, Technology, Application, End User, and Geography
Regions Covered	North America, Europe, Asia–Pacific, Latin America, and Middle East & Africa
Key Companies Mentioned	Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Revvity, Inc. (U.S.), QIAGEN N.V. (Netherlands), Agilent Technologies, Inc. (U.S.), Pacific Biosciences of California, Inc. (U.S.), Danaher Corporation (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Oxford Nanopore Technologies Plc. (U.K.), and MGI Tech Co., Ltd. (China)

FAQs About the Report

What is the focus of the DNA sequencing market study?

The report covers the qualitative analysis and market sizing of the global DNA sequencing market segmented based on offering, technology, application, and end user. This report involves the analysis of various segments of DNA sequencing at the regional and country level. The report also provides insights on factors impacting market growth, regulatory analysis, pricing analysis, and Porter’s five forces analysis.

What is the revenue generated from the sales of DNA sequencing solutions across the globe?

The global DNA sequencing market is projected to reach $ 21.30 billion by 2031 at a CAGR of 11.8% from 2024 to 2031.

Which offering segment is estimated to hold the major share of the market in 2024?

Among all the offerings studied in this report in 2024, the consumables segment is expected to account for the largest share of the DNA sequencing market. The large share of this segment is attributed to increasing demand for consumables from end users, increasing research activities, and the increasing use of DNA sequencing consumables for clinical applications.

Which application segment is estimated to hold the major share of the market in 2024?

Among all the applications studied in this report, in 2024, the research & other applications segment is expected to account for the largest share of the DNA sequencing market. The large share of the segment is attributed to the decreasing cost of sequencing procedures, increasing R&D by pharmaceutical and biotechnology companies for drug discovery, the increasing applications of NGS in multiple clinical and research settings, and the use of informatics solutions to find pharmacological targets, confirm therapeutic hypotheses, and predict the potential safety of inhibitory compounds aimed at molecular targets.

What are the key factors supporting the growth of this market? Also, what are the major opportunities for existing market players and new entrants in the global NGS market?

The growth of this market is driven by several factors: a decline in sequencing costs, a surge in cancer and genetic disorder cases, an increase in the usage of DNA sequencing in diagnostics & precision medicine, a rise in pharmaceutical R&D investments, favorable regulatory & reimbursement policies, an increase in healthcare expenditure, advancements in sequencing technologies, and government policies aimed at promoting genomics research.

Moreover, the expanding scope of DNA sequencing applications, government support for extensive genomic projects, rising adoption of targeted therapies, and untapped potential in emerging nations are expected to offer opportunities for market participants.

Who are the major players operating in the global DNA sequencing market?

The key players operating in the global DNA sequencing market are Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Revvity, Inc. (U.S.), QIAGEN N.V. (Netherlands), Agilent Technologies, Inc. (U.S.), Pacific Biosciences of California, Inc. (U.S.), Danaher Corporation (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Oxford Nanopore Technologies Plc. (U.K.), and MGI Tech Co., Ltd. (China).

Which regions/countries are likely to offer significant growth opportunities for the vendors in this market during the analysis period?

Emerging economies like China and India are projected to offer significant growth opportunities for market vendors. Rapid economic growth and increased government focus on enhancing the healthcare sector in these countries have resulted in substantial investments aimed at improving healthcare accessibility, upgrading infrastructure, and supporting drug discovery and genome mapping initiatives.